New hope for rare kidney cancer: targeted drug plus radiation may replace chemo
NCT ID NCT07498907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for people with a rare cancer of the upper urinary tract (UTUC) that has spread beyond the kidney. Participants must have had surgery and cannot take standard chemo due to health reasons. They will receive either a targeted drug (disitamab vedotin) plus radiation or standard chemo. The goal is to see if the new combo helps prevent cancer from coming back longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could spot bladder Cancer's return
- Can a tiny ultrasound probe see how deep a urinary tract tumor goes?
- Two-Drug combo aims to shrink upper tract bladder cancer before surgery
- Could a drug combo spare bladder cancer patients from surgery?
- New drug duo aims to fight kidney cancer without losing the kidney
- Tiny camera could replace surgery for bladder cancer checks